Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATO + GO in Advanced MDS
NCT00274781Phase 2Completed
- Sponsor
- Cleveland Clinic
- Start
- Feb 2004
- Primary completion
- Dec 2008
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of arsenic trioxide and gemtuzumab ozogamicin in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML), sponsored by Cleveland Clinic. Primary endpoint: Complete and Partial Remission Rate at 12 weeks. Started Feb 2004; status: completed.
02
Drugs
arsenic trioxidegemtuzumab ozogamicin
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT00274781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00274781.